Moclobemide twice daily in the treatment of major depressive episode: A double-blind, multicenter comparison with different three times daily dosage schedules

Abstract

The data on a twice-daily dosage schedule with moclobemide in the treatment of a major depressive episode (MDE) is limited. In this randomized, double-blind, multicenter study, moclobemide, 150 mg twice daily, was compared with two different three times daily regimens with total daily dosages of 300 and 450 mg, respectively, over a 6-week period. Two hundred seventy patients were included, of whom 237 completed the study. The treatment groups were comparable with respect to demographic parameters and severity of depression at baseline. No clear differences between the treatment groups,could be shown with respect to response on the Hamilton Bating Scale for Depression (HAM-D), the Zung Self R..